4
9.67
0.77 (8.65%)
| Penutupan Terdahulu | 8.90 |
| Buka | 8.87 |
| Jumlah Dagangan | 1,877,169 |
| Purata Dagangan (3B) | 1,221,543 |
| Modal Pasaran | 451,612,864 |
| Harga / Jualan (P/S) | 4.98 |
| Harga / Buku (P/B) | 1.66 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 10 Nov 2025 |
| Margin Operasi (TTM) | -383,007.15% |
| EPS Cair (TTM) | -3.18 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -50.00% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 5.08% |
| Nisbah Semasa (MRQ) | 12.36 |
| Aliran Tunai Operasi (OCF TTM) | -153.26 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -90.21 M |
| Pulangan Atas Aset (ROA TTM) | -22.18% |
| Pulangan Atas Ekuiti (ROE TTM) | -32.97% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | 4D Molecular Therapeutics, Inc. | Menaik | Menurun |
AISkor Stockmoo
0.0
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | -2.0 |
| Purata | 0.00 |
|
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 3.88% |
| % Dimiliki oleh Institusi | 95.91% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 33.00 (Barclays, 241.26%) | Beli |
| Median | 32.00 (230.92%) | |
| Rendah | 26.00 (Chardan Capital, 168.87%) | Beli |
| Purata | 30.33 (213.65%) | |
| Jumlah | 3 Beli | |
| Harga Purata @ Panggilan | 10.80 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Barclays | 11 Nov 2025 | 33.00 (241.26%) | Beli | 10.80 |
| Chardan Capital | 11 Nov 2025 | 26.00 (168.87%) | Beli | 10.80 |
| RBC Capital | 11 Nov 2025 | 32.00 (230.92%) | Beli | 10.80 |
| 21 Oct 2025 | 26.00 (168.87%) | Beli | 11.24 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |